Scientific Presentation | AD/PDTM 2022

Study Design and Participant Characteristics of a Phase 2 Trial of Fosgonimeton, a Novel Treatment for Mild-to-Moderate Alzheimer’s Disease

Hans J Moebius, Kevin Church, Kai-Bin Ooi, Joyce Maalouf, William Walker, Philippe L’Hostis, Charles Bernick, , Sam Dickson, Suzanne Hendrix, and Xue Hua

Download PDF